Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enflicoxib SCHEMBL26427 | 0.89 | PTGS1 (0.66) | PTGS1PTGS2 | |
| SCHEMBL5856621 | 0.85 | CA12 (0.52) | PDE5APTGS1PTGS2 | |
| SCHEMBL5713130 | 0.82 | PTGS1 (0.47) | PDE5APTGS1PTGS2 | |
| SCHEMBL5713135 | 0.81 | PDE5A (0.60) | PDE5APTGS1PTGS2 | |
| SCHEMBL5856546 | 0.80 | PTGS1 (0.66) | PTGS1PTGS2 | |
| SCHEMBL5856792 | 0.78 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5857642 | 0.78 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5858890 | 0.78 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5857443 | 0.76 | CA2 (0.64) | PTGS1PTGS2 | |
| SCHEMBL6560048 | 0.76 | PTGS1 (0.60) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408035-B1 | METHOD OF PREPARING DERIVATIVES OF 1.5-DIARYL-3-TRIFLUOROMETHYL-DELTA2-PYRAZOLINES THAT ARE RACEMIC AND ENANTIOMERICALLY PURE | ESTEVE LABOR DR (ES) | 2006-01-04 | — | — | EP | disclosed |
| US-20050096373-A1 | Procedure for the preparation of racemic and enantiomerically pure derivatives O F 1,5 diaryl-3-trifluorromethyl-delta2-pyrazolines | LABORATORIES DEL DR. ESTEVE, S.A. | 2005-05-05 | — | — | US | disclosed |
| US-20050096474-A1 | Procedure for the preparation of racemic derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines | LABORATORIES DEL DR. ESTEVE, S.A. | 2005-05-05 | — | — | US | disclosed |
| US-6846935-B2 | Procedure for the preparation of racemic and enantionmerically pure derivatives of 1,5-diaryl-3-trifluoromethyl-Δ2-pyrazolines | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-01-25 | — | — | US | disclosed |
| EP-1408035-A1 | METHOD OF PREPARING DERIVATIVES OF 1.5-DIARYL-3-TRIFLUOROMETHYL-DELTA2-PYRAZOLINES THAT ARE RACEMIC AND ENANTIOMERICALLY PURE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-04-14 | — | — | EP | disclosed |
| US-20040019222-A1 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines that are racemic and enantiomerically pure | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096474-A1 | Procedure for the preparation of racemic derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines | CLIC1, PEAK1, SIGMAR1 | PDE5A 1356/4885PTGS1 1307/4885PTGS2 3685/4885 |
| US-20040019222-A1 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines that are racemic and enantiomerically pure | CLIC1, SRD5A1, PEAK1 | PDE5A 1166/4885PTGS1 1227/4885PTGS2 3156/4885 |
| US-20050096373-A1 | Procedure for the preparation of racemic and enantiomerically pure derivatives O F 1,5 diaryl-3-trifluorromethyl-delta2-pyrazolines | CLIC1, SRD5A1, PEAK1 | PDE5A 1483/4885PTGS1 1253/4885PTGS2 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.